1. Genetic polymorphism inIFNL4and response to pegylated interferon-α and ribavirin in Japanese chronic hepatitis C patients
- Author
-
Susumu Morita, Kaname Yoshizawa, Akihiro Matsumoto, Eiji Tanaka, Satoru Joshita, Soichiro Shibata, Takefumi Kimura, Yuichi Nozawa, Yoshihiko Katsuyama, Masao Ota, Michiharu Komatsu, and Takeji Umemura
- Subjects
Predictive marker ,business.industry ,Ribavirin ,Hepatitis C virus ,Immunology ,Single-nucleotide polymorphism ,General Medicine ,Odds ratio ,medicine.disease_cause ,Biochemistry ,chemistry.chemical_compound ,chemistry ,Pegylated interferon ,Interferon ,Genotype ,Genetics ,Immunology and Allergy ,Medicine ,business ,medicine.drug - Abstract
A genetic polymorphism of the newly discovered interferon-λ 4 (IFNL4) gene was associated with hepatitis C virus (HCV) clearance in individuals of African ancestry. To assess whether a dinucleotide variant of IFNL4 (ss469415590) also affected treatment outcome of antiviral therapy in Japan, we genotyped 213 patients with chronic genotype 1 HCV infection and 176 healthy subjects. The ΔG allele was associated with treatment failure [odds ratio (OR) 4.73, P = 0.019], as was the IFL3 rs8099917 single nucleotide polymorphism (SNP) (OR 5.06, P = 0.068). The correlation between ss469415590 and rs8099917 was high (r(2) = 0.92, D' = 0.98). Multivariate analysis revealed that the rs8099917 SNP was independently associated with treatment failure (OR 5.28, P = 0.009). Therefore, ss469415590 may be another predictive marker of antiviral therapy outcome in the Japanese population.
- Published
- 2013